Background:We investigated anti-diabetic, hypolipedimic and antioxidant activity of hydroalcoholic extract from leaves and fruit peel of Punica granatum.Materials and Methods:Streptozotocin induced diabetic Wister rats were used in this study consisting of seven groups of six animals each. Groups (1) normal control, (2) diabetic control, (3) leaves extract 100 mg/kg b.w. of P. granatum, (4) leaves extract 200 mg/kg b.w. of P. granatum, (5) fruit peel extract 100 mg/kg b.w. of P. granatum, (6) peel extract 200 mg/kg b.w. of P. granatum and (7) glibenclamide respectively. Fasting blood sugar was recorded on 1st, 7th, 14th, 21st and 28th day. At the end of the experiment Lipid profile and levels of antioxidants were determined. Safety profile of both extracts was evaluated using acute and chronic toxicity studies.Results:Higher dose of fruit peel extract of P. granatum (PEPG) and glibenclamide significantly lowered blood glucose level from 7th day onwards however glibenclamide was found to be more effective. Leaves extract at higher dose and fruit extract at lower dose also significantly lowered blood glucose level from 14th day onwards. Leaves extract at lower dose also significantly lowered blood glucose level from 21st day onwards. Glibenclamide and higher dose of fruit PEPG extract significantly reduced the total cholesterol, triglyceride levels and significantly increased the high density lipoprotein cholesterol level. Glibenclamide followed by higher dose was found more effective in reducing plasma thiobarbituric acid reactive substances and increasing levels of antioxidant enzymes (superoxide dismutase and catalase). No toxicity was observed even when both extracts were administered at 10 times of higher dose used in this study and no significant changes were seen when it were used chronically.Conclusion:Leaves and fruit PEPG possesses significant anti-diabetic, hypolipedimic and antioxidant properties. This study supports the traditional use of P. granatum in diabetes. Fruit peel which is normally thrown by many while eating pomegranate fruit is having anti-diabetic, hypolipedimic and Antioxidant activity. Furthermore high therapeutic index is safe for chronic use.
Background: Medicinal plants play a major role in controlling diabetes by producing microstructural changes in liver and pancreas. Quantification of islets and hepatocytes by using histomorphometric tools are effective in evaluating the antidiabetic action of drugs. Aims and Objectives:To assess the anti diabetic properties of alcoholic extracts of Mucuna Pruriens seeds (200 mg/kg b.w) by means of histological and histomorphometric analysis of pancreas and liver .Methods: Seventy two neonatal wistar rats were randomly divided into four groups, i.e. Normal , Diabetic control, diabetic rats treated with Mucuna and Glibenclamide. Diabetes was induced by a single intraperitoneal administration of streptozotocin (65mg/kg b.w) in 5 day old neonatal rats (n =54).12 weeks after the injection, animals were divided in to four groups with 18 animals in each. The study groups were as follows. Group A -Normal control, Group B -STZ untreated, Group C -Mucuna Pruriens 200mg/kg, Group D -Glibenclamide (1mg/kg). Fasting blood sugar levels were monitored once a week during the drug study .i.e. 12 weeks. At the end of every 4th week, 6 animals from each group were sacrificed for histological and histomorphometric studies on liver and Pancreas. Results:From the histological studies, the diabetic group showed reduction of cell population in the pancreas and depletion of the number of hepatocytes in the liver. After 12 weeks of Drug treatment, These changes were markedly reduced in Mucuna Pruriens treated group. The obtained results were further quantified by means of Histomorphometric analysis and the results showed reduction in the number and diameter of islets, number of beta cells and number of healthy hepatocytes in diabetic control group and treatment with Mucuna Pruriens seed extract significantly reversed these changes (p < 0.05)
Tuberculosis is a pandemic, chronic infectious disease which affects more than 10 million people in the world. About 3.5% of patients of newly diagnosed have reported having multidrug-resistant tuberculosis (MDR-TB). The standard treatment of MDR-TB has many cons like high cost, less effectiveness, and more drug interactions. Thus, to overcome these disadvantages a new novel compound which belongs to the diarylquinolone group called bedaquiline has been developed as a part of combination therapy in adults with MDR-TB for its bactericidal activity. It mainly acts by inhibiting the adenosine triphosphate synthase enzyme of Mycobacterium tuberculosis. This drug was introduced as a new addition to the standard TB regimen after 50 years.
Background:To investigate the anti-cobra venom effect of alcoholic extract of Andrographis paniculata.Materials and Methods:After calculating the LD99 of snake venom, the venom-neutralizing ability of plant extract at the dose 1 g/kg and 2 g/kg was determined using in vitro and in vivo methods. The alleviation in the mean survival time of the animals were used to infer the antivenom property of the drug after challenging with LD99 of snake venom.Results:The ethanolic extract of plant A. paniculata significantly increases mean survival time and the protection fold, but could not protect animals from death when used alone. The higher dose, i.e., 2 g/kg was found better than that of the lower. ASV was found more effective than the plant extract. When ASV was given along with plant extract, it potentiates its effect.Conclusion:The observation demonstrates the anti-cobra venom activity of ethanolic extract of A. paniculata which is comparable with ASV.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.